AI Stock Analysis - Janux Therapeutics (JANX)
Analysis generated January 20, 2026.
Janux Therapeutics is a biotech company focused on developing innovative cancer treatments through its proprietary technology platform. The company aims to harness the power of immunotherapy to treat cancer more effectively. Its core technology is designed to enhance the potency and safety profiles of cancer-targeting therapies, offering a potentially transformative impact on how cancer is managed and treated.
Stock Alerts - Janux Therapeutics (JANX)
 |
Janux Therapeutics | March 4 Price is up by 6% in the last 24h. |
|
Janux Therapeutics | February 6 Price is up by 6.7% in the last 24h. |
|
Janux Therapeutics | February 5 Price is down by -6.2% in the last 24h. |
|
Janux Therapeutics | January 22 Price is up by 7.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Janux Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 13 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,657 | Sign up | Sign up | Sign up |
| X Followers | 142 | Sign up | Sign up | Sign up |
| X Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 107 | Sign up | Sign up | Sign up |
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
| Price | $13.95 |
| Target Price | Sign up |
| Volume | 971,968 |
| Market Cap | $856M |
| Year Range | $12.18 - $34.74 |
| Dividend Yield | 0% |
| Analyst Rating | 92% buy |
| Industry | Biotechnology |
In the news
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune TrialMarch 1 - Yahoo Entertainment |
|
 |
Vir Biotechnology: The Low-Down On The Readouts AheadFebruary 5 - SeekingAlpha |
 |
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos ExpansionJanuary 22 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 10M | 500,000 | 9.5M | -24M | -24M | -0.390 |
| Q2 '25 | 0 | 540,000 | -540,000 | -34M | -45M | -0.550 |
| Q1 '25 | 0 | 520,000 | -520,000 | -24M | -34M | -0.380 |
| Q4 '24 | -8.5M | 510,000 | -9.6M | -20M | -29M | -0.360 |
| Q3 '24 | 440,000 | 510,000 | 440,000 | -28M | -35M | -0.510 |
Insider Transactions View All
| Campbell David Alan filed to sell 284,982 shares at $13.7. January 2 '26 |
| Meyer Andrew Hollman filed to sell 83,095 shares at $13.7. January 2 '26 |
| Winter Charles M. filed to sell 77,721 shares at $13.7. January 2 '26 |
| DiRaimondo Thomas filed to sell 124,425 shares at $13.7. January 2 '26 |
| Dobek Maria filed to sell 15,373 shares at $13.7. January 2 '26 |
Similar companies
Read more about Janux Therapeutics (JANX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Janux Therapeutics
The Market Cap of Janux Therapeutics is $856M.
Currently, the price of one share of Janux Therapeutics stock is $13.95.
The JANX stock price chart above provides a comprehensive visual representation of Janux Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Janux Therapeutics shares. Our platform offers an up-to-date JANX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Janux Therapeutics (JANX) does not offer dividends to its shareholders. Investors interested in Janux Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Janux Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
